已收盤 08-07 16:00:00 美东时间
+1.410
+0.88%
Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY) was in merger talks with AstraZeneca (AZN), a development that was later denied by...
19分钟前
The U.S. Medical Devices ETF (IHI) could be nearing a technical breakout as strength in the broader healthcare sector prompts investors to rotate into lagging industry groups, according to Donovan Jac...
08-07 23:07
8月7日,CDE官网公示,赛诺菲(SNY.US)尼塞韦单抗注射液一项新适应症上市申请获得受理,注册分类为3.1类。根据公开信息和临床试验进展,Insight数据...
08-07 15:38
(来源:经济日报) 转自:经济日报 据英国媒体报道,英国阿斯利康与美国百时美施贵宝正就合并事宜展开谈判。一旦落地,将诞生一家市值近4000亿美元的制药巨头,跻身...
08-07 15:25
核心要点 有报道称两大药企巨头洽谈合并。依托百时美施贵宝深耕美国的业务,阿斯利康可一举获得美国市场规模,但代价是增长放缓,并承担巨大整合风险。 相关...
08-06 18:24
8月6日,石药集团(01093.HK)高开震荡,截至收盘,公司股价涨1.49%,报8.5港元,市值979.41亿港元。 8月5日晚间公司发布重磅合作公告,宣布与...
08-06 16:23
(来源:求实药社) 2026年8月5日,石药集团与阿斯利康正式签署合资合同,在石家庄共建新一代生物制剂生产基地。根据协议,石药集团持股51%,阿斯利康持股49...
08-06 12:10
Corbus Pharmaceuticals reported progress in its oncology and obesity pipeline, obtaining FDA clearance for the registrational study of CRB-701 in oropharyngeal cancer and completing the last patient visit in the CANYON-1 trial of CRB-913 for obesity. The company also appointed new leadership to strengthen its team. Financially, Corbus reported a net loss of $35 million for the second quarter, with $117.9 million in cash on hand.
08-06 12:00
(来源:东四十条资本) 一家曾差点被同行吞下的公司,十二年后坐到了全球医药行业最大一张牌桌的主位。 近日,英国《金融时报》爆料称,阿斯利康与百时美施贵宝正...
08-06 10:21